Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe
Odile Launay, David J M Lewis, Alessandra Anemona, Pierre Loulergue, Jo Leahy, Antonella Silvia Sciré, Anaïs Maugard, Elisa Marchetti, Stefano Zancan, Zhiming Huo, Simona Rondini, Rachid Marhaba, Oretta Finco, Laura B Martin, Jochen Auerbach, Daniel Cohen, Allan Saul, Christiane Gerke, Audino Podda, Odile Launay, David J M Lewis, Alessandra Anemona, Pierre Loulergue, Jo Leahy, Antonella Silvia Sciré, Anaïs Maugard, Elisa Marchetti, Stefano Zancan, Zhiming Huo, Simona Rondini, Rachid Marhaba, Oretta Finco, Laura B Martin, Jochen Auerbach, Daniel Cohen, Allan Saul, Christiane Gerke, Audino Podda
Abstract
Background: Approximately 164,000 deaths yearly are due to shigellosis, primarily in developing countries. Thus, a safe and affordable Shigella vaccine is an important public health priority. The GSK Vaccines Institute for Global Health (GVGH) developed a candidate Shigella sonnei vaccine (1790GAHB) using the Generalized Modules for Membrane Antigens (GMMA) technology. The paper reports results of 1790GAHB Phase 1 studies in healthy European adults.
Methods: To evaluate the safety and immunogenicity profiles of 1790GAHB, we performed two parallel, phase 1, observer-blind, randomized, placebo-controlled, dose escalation studies in France ("study 1") and the United Kingdom ("study 2") between February 2014 and April 2015 (ClinicalTrials.gov, number NCT02017899 and NCT02034500, respectively) in 18-45years old subjects (50 in study 1, 52 in study 2). Increasing doses of Alhydrogel adsorbed 1790, expressed by both O Antigen (OAg) and protein quantity, or placebo were given either by intramuscular route (0.059/1, 0.29/5, 1.5/25, 2.9/50, 5.9/100μg of OAg/μg of protein; study 1) or by intradermal (ID), intranasal (IN) or intramuscular (IM) route of immunization (0.0059/0.1, 0.059/1, 0.59/10μg ID, 0.29/5, 1.2/20, 4.8/80μg IN and 0.29/5μg IM, respectively; study 2). In absence of serologic correlates of protection for Shigella sonnei, vaccine induced immunogenicity was compared to anti-LPS antibody in a population naturally exposed to S. sonnei.
Findings: Vaccines were well tolerated in both studies and no death or vaccine related serious adverse events were reported. In study 1, doses ≥1.5/25μg elicited serum IgG median antibody greater than median level in convalescent subjects after the first dose. No vaccine group in study 2 achieved median antibody greater than the median convalescent antibody.
Interpretation: Intramuscularly administered Shigella sonnei GMMA vaccine is well tolerated, up to and including 5.9/100μg and induces antibody to the OAg of at least the same magnitude of those observed following natural exposure to the pathogen. Vaccine administered by ID or IN, although well tolerated, is poorly immunogenic at the doses delivered. The data support the use of the GMMA technology for the development of intramuscular multivalent Shigella vaccines.
Keywords: Clinical study; GMMA; Shigella sonnei; Vaccine.
Copyright © 2017 GlaxoSmithKline SA. Published by Elsevier B.V. All rights reserved.
Figures
References
- Bardhan P., Faruque A.S., Naheed A., Sack D.A. Decrease in shigellosis-related deaths without Shigella spp.-specific interventions, Asia. Emerg. Infect. Dis. 2010;16(11):1718–1723.
- Bowen A., Hurd J., Hoover C. Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin - United States, May 2014–February 2015. MMWR Morb. Mortal. Wkly Rep. 2015;64(12):318–320.
- Camacho A.I., Irache J.M., Gamazo C. Recent progress towards development of a Shigella vaccine. Expert Rev. Vaccines. 2013;12(1):43–55.
- Cohen D., Block C., Green M.S., Lowell G., Ofek I. Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections. J. Clin. Microbiol. 1989;27(1):162–167.
- Cohen D., Green M.S., Block C., Slepon R., Ofek I. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J. Clin. Microbiol. 1991;29(2):386–389.
- Cohen D., Ashkenazi S., Green M.S. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet. 1997;349(9046):155–159.
- Ekdahl K., Andersson Y. The epidemiology of travel-associated shigellosis—regional risks, seasonality and serogroups. J. Inf. Secur. 2005;51(3):222–229.
- Ferreccio C., Prado V., Ojeda A. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am. J. Epidemiol. 1991;134(6):614–627.
- Fries L.F., Montemarano A.D., Mallett C.P., Taylor D.N., Hale T.L., Lowell G.H. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun. 2001;69(7):4545–4553.
- GBD 2015 Mortality and Causes of Death Collaborators Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–1544.
- Gerke C., Colucci A.M., Giannelli C. Production of a Shigella sonnei vaccine based on generalized modules for membrane antigens (GMMA), 1790GAHB. PLoS One. 2015;10(8)
- Gu B., Cao Y., Pan S. Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe-America and Asia-Africa from 1998 to 2009. Int. J. Antimicrob. Agents. 2012;40(1):9–17.
- Herrington D.A., Van de Verg L., Formal S.B. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine. 1990;8(4):353–357.
- Kaminski R.W., Oaks E.V. Inactivated and subunit vaccines to prevent shigellosis. Expert Rev. Vaccines. 2009;8(12):1693–1704.
- Klontz K.C., Singh N. Treatment of drug-resistant Shigella infections. Expert Rev. Anti-Infect. Ther. 2015;13(1):69–80.
- Kotloff K.L., Nataro J.P., Losonsky G.A. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine. 1995;13(16):1488–1494.
- Kotloff K.L., Winickoff J.P., Ivanoff B. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull. World Health Organ. 1999;77(8):651–666.
- Kotloff K.L., Nataro J.P., Blackwelder W.C. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet. 2013;382(9888):209–222.
- Kubler-Kielb J., Schneerson R., Mocca C., Vinogradov E. The elucidation of the structure of the core part of the LPS from Plesiomonas shigelloides serotype O17 expressing O-polysaccharide chain identical to the Shigella sonnei O-chain. Carbohydr. Res. 2008;343(18):3123–3127.
- Levine M.M., Kotloff K.L., Barry E.M., Pasetti M.F., Sztein M.B. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat. Rev. Microbiol. 2007;5(7):540–553.
- Lindsay B., Ochieng J.B., Ikumapayi U.N. Quantitative PCR for detection of Shigella improves ascertainment of Shigella burden in children with moderate-to-severe diarrhea in low-income countries. J. Clin. Microbiol. 2013;51(6):1740–1746.
- Liu J., Kabir F., Manneh J. Development and assessment of molecular diagnostic tests for 15 enteropathogens causing childhood diarrhoea: a multicentre study. Lancet Infect. Dis. 2014;14(8):716–724.
- Livio S., Strockbine N.A., Panchalingam S. Shigella isolates from the global enteric multicenter study inform vaccine development. Clin. Infect. Dis. 2014;59(7):933–941.
- Lozano R., Naghavi M., Foreman K. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128.
- Maggiore L., Yu L., Omasits U. Quantitative proteomic analysis of Shigella flexneri and Shigella sonnei generalized modules for membrane antigens (GMMA) reveals highly pure preparations. Int. J. Med. Microbiol. 2016;306(2):99–108.
- Mani S., Wierzba T., Walker R.I. Status of vaccine research and development for Shigella. Vaccine. 2016;34(26):2887–2894.
- Muturi-Kioi V., Lewis D., Launay O. Neutropenia as an adverse event following vaccination: results from randomized clinical trials in healthy adults and systematic review. PLoS One. 2016;11(8)
- Passwell J.H., Ashkenzi S., Banet-Levi Y. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine. 2010;28(10):2231–2235.
- Slifka M.K., Ahmed R. Limiting dilution analysis of virus-specific memory B cells by an ELISPOT assay. J. Immunol. Methods. 1996;199(1):37–46.
- Toneatto D., Ismaili S., Ypma E., Vienken K., Oster P., Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum. Vaccin. 2011;7(6):646–653.
- Wahid R., Simon J.K., Picking W.L., Kotloff K.L., Levine M.M., Sztein M.B. Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. Clin. Immunol. 2013;148(1):35–43.
- Zaman M., Chandrudu S., Toth I. Strategies for intranasal delivery of vaccines. Drug Deliv. Transl. Res. 2013;3(1):100–109.
- Zehrung D., Jarrahian C., Wales A. Intradermal delivery for vaccine dose sparing: overview of current issues. Vaccine. 2013;31(34):3392–3395.
- Zychlinsky A., Perdomo J.J., Sansonetti P.J. Molecular and cellular mechanisms of tissue invasion by Shigella flexneri. Ann. N. Y. Acad. Sci. 1994;730:197–208.
Source: PubMed